Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

R&D Roundup, November 2019: LimFlow Starts Pivotal Trial Of Peripheral Shunt; Conservative Coronary Treatment Matches Intervention In Trial

Executive Summary

An overview of November’s 10 most-read Medtech Insight articles on topics related to research and development of new medical technology.

You may also be interested in...



LimFlow On Target For 2021 US Launch Of Deep Vein Arterialization System

The results from the PROMISE I feasibility study give LimFlow confidence that the PROMISE II pivotal trial will prove that the LimFlow percutaneous deep vein arterialization system is a safe and effective alternative to amputation for patients with critical limb ischemia.

AHA 2019: French Registry Data Favor Edwards’ Sapien TAVR Over Medtronic’s CoreValve

Registry data from France shows transcatheter aortic valve replacement patients have better outcomes with Edwards’ Sapien balloon-expandable valves than with Medtronic’s CoreValve self-expanding valves.

AHA 2019: Conservative Approach Works As Well As Intervention For Stable Coronary Disease In ISCHEMIA Trial

The long-awaited results of the ISCHEMIA trial showed that patients with asymptomatic stable coronary disease get no apparent benefit from coronary intervention compared to a more conservative strategy with optimal medical management.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT125983

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel